Neurocrine Biosciences, Inc.

Stocks

NBIX

US64125C1099

Real-time Estimate Cboe BZX Other stock markets 12:26:58 21/07/2026 am IST			5-day change	1st Jan Change
174.30 ^USD	+2.00%		-0.13%	+22.59%

13/07	Wedbush Lifts Price Target on Neurocrine Biosciences to $185 From $176, Keeps Outperform Rating	MT
10/07	Neurocrine Biosciences Insider Sold Shares Worth $2,603,112, According to a Recent SEC Filing	MT

Transcript : Neurocrine Biosciences, Inc. Presents at 46th Annual William Blair Growth Stock Conference, Jun-02-2026 10

Published on 06/02/2026 at 10:35 pm IST - Modified on 06/02/2026 at 11:20 pm IST

S&P Capital IQ

Add MarketScreener to your sources

Presenter Speech
Myles Minter (Analysts)

Thank you everyone for joining us here at the 46th William Blair Annual Growth Stock Conference. I haven't been here for all 46 years, but I have been here for

This article is reserved for subscribers

Unlock the article : SUBSCRIBE!

Already a customer? Log In

Add MarketScreener to your sources

Latest news about Neurocrine Biosciences, Inc.

13/07	Wedbush Lifts Price Target on Neurocrine Biosciences to $185 From $176, Keeps Outperform Rating	MT
10/07	Neurocrine Biosciences Insider Sold Shares Worth $2,603,112, According to a Recent SEC Filing	MT
07/07	RBC Capital Adjusts Neurocrine Biosciences Price Target to $195 From $183, Maintains Outperform Rating	MT
02/07	Neurocrine Begins Phase 2 Trial of Crinecerfont in Children Under 4 Years With Classic CAH Genetic Condition	MT
02/07	Neurocrine Biosciences Initiates Phase 2 Study of Crinecerfont in Pediatric Patients Under 4 Years Old with Classic Congenital Adrenal Hyperplasia	CI
01/07	Neurocrine Biosciences' Ingrezza Momentum Seen Supporting 2026 Guidance Upgrade, UBS Says	MT
29/06	Neurocrine Biosciences, Inc.(NasdaqGS:NBIX) dropped from Russell 1000 Dynamic Index	CI
22/06	Deutsche Bank Raises Neurocrine Biosciences Price Target to $170 From $155, Maintains Hold Rating	MT
16/06	Neurocrine Biosciences, Inc. Presents First Retrospective Case Series Of CRENESSITY (Crinecerfont) In Patients With Classic Congenital Adrenal Hyperplasia Due To 11B-Hydroxylase Deficiency At ENDO 2026	CI
16/06	Neurocrine Biosciences, Inc. Announces Clinical Findings from the First Retrospective Case Series	CI
15/06	Neurocrine Biosciences Presents New Two-Year CRENESSITY Data Demonstrating Improvements in Cardiometabolic Outcomes in Adults With Classic Congenital Adrenal Hyperplasia	CI
09/06	Neurocrine Biosciences, Inc. Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026, Jun-09-2026 09:20 AM
09/06	Neurocrine Biosciences Late-Stage Study Shows Promising Results for Tardive Dyskinesia Drug	MT
09/06	Neurocrine Biosciences Presents New Clinically Meaningful Response Data on Treatment of Tardive Dyskinesia Reinforcing the Efficacy of INGREZZA Capsules Across A Broad Range of Patients	CI
08/06	Neurocrine Biosciences Presents New Data Highlighting Functional and Socio-Emotional Improvements with Ingrezza Capsules in Individuals with Tardive Dyskinesia and Intellectual and Developmental Disabilities	CI